Form 8-K - Current report:
SEC Accession No. 0001625297-26-000021
Filing Date
2026-05-04
Accepted
2026-05-04 07:00:24
Documents
13
Period of Report
2026-05-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K indv-20260504.htm   iXBRL 8-K 29293
2 EX-99.1 ex991asrpressreleasemay420.htm EX-99.1 10909
6 GRAPHIC image_0a.jpg GRAPHIC 8966
  Complete submission text file 0001625297-26-000021.txt   172944

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT indv-20260504.xsd EX-101.SCH 1773
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT indv-20260504_lab.xml EX-101.LAB 21615
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT indv-20260504_pre.xml EX-101.PRE 12502
16 EXTRACTED XBRL INSTANCE DOCUMENT indv-20260504_htm.xml XML 3141
Mailing Address 10710 MIDLOTHIAN TURNPIKE SUITE 125 NORTH CHESTERFIELD VA 23235
Business Address 10710 MIDLOTHIAN TURNPIKE SUITE 125 NORTH CHESTERFIELD VA 23235 804-379-1090
Indivior Pharmaceuticals, Inc. (Filer) CIK: 0001625297 (see all company filings)

EIN.: 412520873 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37835 | Film No.: 26934579
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)